Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lefever

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 22, 2016
Covalently deposited dyes: a new chromogen paradigm that facilitates analysis of multiple biomarkers in situWilliam A Day, Mark R Lefever, Robert L Ochs, et al.
BMC Musculoskeletal Disorders|January 18, 2011
Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animalsRichard T Hinkle, Frank R Lefever, Elizabeth T Dolan, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 16, 2017
Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodiesWenjun Zhang, Antony Hubbard, Tobin Jones, et al.
BMC Medicine|July 14, 2007
Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceRichard T Hinkle, Frank R Lefever, Elizabeth T Dolan, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 22, 2016
Covalently deposited dyes: a new chromogen paradigm that facilitates analysis of multiple biomarkers in situWilliam A Day, Mark R Lefever, Robert L Ochs, et al.
BMC Musculoskeletal Disorders|January 18, 2011
Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animalsRichard T Hinkle, Frank R Lefever, Elizabeth T Dolan, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 16, 2017
Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodiesWenjun Zhang, Antony Hubbard, Tobin Jones, et al.
BMC Medicine|July 14, 2007
Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceRichard T Hinkle, Frank R Lefever, Elizabeth T Dolan, et al.
Pageof 5